- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
The House Budget Committee wants to know whether the Congressional Budget Office (CBO) is continually updating its analysis of how the Inflation Reduction Act’s drug price controls will affect pharmaceutical innovation, noting new data have emerged since CBO initially estimated the law will lead to 13 fewer drugs coming to market over the next 30 years.
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us